Published in Pathol Biol (Paris) on September 01, 1996
Letter: Creatinine clearance: bedside estimate. Ann Intern Med (1973) 2.52
An improved method of digoxin therapy. Ann Intern Med (1968) 2.19
Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother (1997) 2.13
Estimation of creatinine clearance when urine cannot be collected. Lancet (1971) 1.61
Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit (2001) 1.50
A nomogram for digoxin therapy. Am J Med (1974) 1.38
Reducation of digitalis toxicity by computer-assisted glycoside dosage regimens. Ann Intern Med (1972) 1.30
Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother (1999) 1.21
Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother (1990) 1.13
Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis (2004) 1.11
Clinical studies with computer-assisted initial lidocaine therapy. Arch Intern Med (1984) 1.11
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant (2001) 1.06
Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit (1994) 1.01
Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clin Pharmacol Ther (1991) 1.01
Diurnal changes in the pharmacokinetic behavior of amikacin. Ther Drug Monit (2000) 0.96
Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob Agents Chemother (1998) 0.96
Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy (2001) 0.95
An improved method of digitoxin therapy. Ann Intern Med (1970) 0.94
Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy (1999) 0.92
Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant (2003) 0.92
Serum cardiac glycoside assay based upon displacement of 3 H-ouabain from Na-K ATPase. Circulation (1972) 0.90
Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. J Clin Pharm Ther (2006) 0.90
Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm. Clin Pharmacokinet (1992) 0.90
Estimation of creatinine clearance from changing serum-creatinine levels. Lancet (1971) 0.88
Factors to consider in planning digoxin therapy. J Chronic Dis (1971) 0.87
Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. J Clin Pharm Ther (2004) 0.86
The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care (1991) 0.86
Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother (2000) 0.85
Comparison of four methods for predicting serum gentamicin concentrations in surgical patients with perforated or gangrenous appendicitis. Clin Pharm (1987) 0.85
Death from weight-control pills. A case report with objective postmortem confirmation. JAMA (1969) 0.83
Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant (2003) 0.83
Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother (2002) 0.82
Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol (2001) 0.81
[Cardiovascular impact of end-stage renal insufficiency in children undergoing hemodialysis]. Arch Mal Coeur Vaiss (2000) 0.81
Computer-controlled administration of cardiovascular drugs. Prog Cardiovasc Dis (1983) 0.81
How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporine. Eur J Clin Pharmacol (1996) 0.81
Adaptive control of therapeutic drug regimens relations between clinical situations: outcomes and simulations using nonlinear dynamic models. Medinfo (1995) 0.81
Open-loop-feedback control of serum drug concentrations: pharmacokinetic approaches to drug therapy. Med Instrum (1983) 0.80
Editorial: Quantitative aspects of clinical judgment. Am J Med (1973) 0.79
Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage. J Clin Pharm Ther (2001) 0.79
[Aminoglycoside determinations calculated in endocarditis vegetations. Relations with clinical practices during infectious endocarditis treatment with amikacin]. Therapie (1994) 0.78
Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. Biol Neonate (2001) 0.78
In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. Acta Ophthalmol (Copenh) (1991) 0.78
Goal-oriented, model-based drug regimens. Comput Biol Med (2001) 0.77
Administration of digoxin. Dis Chest (1969) 0.77
Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. Comput Biol Med (2001) 0.77
A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. Ther Drug Monit (1998) 0.77
Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. J Clin Pharm Ther (2004) 0.76
Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. Int J Biomed Comput (1994) 0.76
Antibiotic dose adjustment in renal insufficiency. Lancet (1992) 0.75
Sodium hyaluronate as a carrier for intravitreal gentamicin. An experimental study. Acta Ophthalmol (Copenh) (1991) 0.75
Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy. J Clin Pharm Ther (2010) 0.75
Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. J Antimicrob Chemother (1998) 0.75
Computerized dosage regimens for highly toxic drugs. Am J Hosp Pharm (1974) 0.75
N-Acetylprocainamide kinetics and clinical response during repeated dosing. Clin Pharmacol Ther (1982) 0.75
Computation of drug concentrations in endocardial vegetations in patients during antibiotic therapy. Int J Biomed Comput (1994) 0.75
An improved method for replacing one digitalis glycoside with another. Med Times (1970) 0.75
Planning drug doses for patients. Dent Dimens (1973) 0.75
Common medical causes of headache. J Hosp Dent Pract (1969) 0.75
The dental patient and the medical history. J Hosp Dent Pract (1967) 0.75
[Ligamento-pubic fixation and its value in urinary incontinence associated with prolapse]. J Gynecol Obstet Biol Reprod (Paris) (1972) 0.75
Clinical applications of pharmacokinetics and adaptive control. IEEE Trans Biomed Eng (1987) 0.75
Autopsy verification of suicide by digitalis. Report of a case, with successful chemical identification of digitalis glycosides in gastric contents. Am J Clin Pathol (1967) 0.75
[Biological diagnosis of immediate drug allergy. Comparative study of histamine liberation tests and CD63 expression by flow cytometry (preliminary results)]. Allerg Immunol (Paris) (1999) 0.75
[The hospital course of thrombolyzed myocardial infarction: role of bypass and angioplasty]. Ann Cardiol Angeiol (Paris) (1990) 0.75
Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients. Int J Biomed Comput (1994) 0.75
Digitalis therapy: simple formulas to plan and adjust dosage regimens. MD Comput (1984) 0.75
Determination of ceftazidime in plasma using high-performance liquid chromatography and electrochemical detection. Application for individualizing dosage regimens in elderly patients. J Chromatogr B Biomed Sci Appl (1998) 0.75
[PK/PD modeling of aminoglycoside nephrotoxicity]. Pathol Biol (Paris) (2003) 0.75
Kinetics of procainamide in anuric patients undergoing chronic hemodialysis. Proc Clin Dial Transplant Forum (1973) 0.75
A graphical user interface to facilitate patient-specific drug dosing. J Med Syst (1993) 0.75
Gentamicin and kanamycin nomograms. Ann Intern Med (1972) 0.75
Drug-receptor relationships, selection of therapeutic goals, and adaptive control of pharmacokinetic systems. Fed Proc (1987) 0.75
Automatic regulation for administration of therapeutic agents. IEEE Trans Biomed Eng (1987) 0.75
[Adaptive control of therapeutics using amikacin in very old patients: retrospective analysis of efficacy and toxicity]. Pathol Biol (Paris) (1994) 0.75
[Some peculiar colposcopic images in infection of the cervix]. Gynecol Obstet (Paris) (1968) 0.75
Electrolytes and cardiac arrhythmias. Crit Care Update (1980) 0.75
A fluorometric determination of myocardial digoxin at autopsy, with identification of digitalis leaf, digitoxin, and gitoxin. Am J Clin Pathol (1969) 0.75